On June 26, Hims & Hers Health rose 5.54% in regular trading, trading at $34.48 per share, with turnover of approximately $205 million. The rally was driven by Barclays significantly raising its target price on the stock from $29 to $39 while maintaining an Overweight rating, providing a strong catalyst for the rebound.

The upgraded target price represents meaningful upside from current levels and signals renewed institutional confidence in the telehealth platform's growth trajectory. The move also follows a period of pronounced selling pressure — shares had dropped sharply after the company disclosed a proposed securities offering on June 23, which triggered profit-taking after a prior 22% rally from $28.91 to $35.47. The stock had further declined to $30.95 on June 25 as dilution concerns persisted.

Hims & Hers Health operates a multi-specialty telehealth platform connecting consumers with licensed healthcare professionals across mental health, sexual health, dermatology, and primary care verticals. The company was founded in 2017 and is headquartered in San Francisco, CA.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)